NEW YORK – Adaptive Biotechnologies and GlaxoSmithKline announced late Tuesday a collaboration to use Adaptive's ClonoSeq assay to assess minimal residual disease (MRD) across GSK's portfolio of hematology products.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.